Prescription Only
This is an FDA-approved prescription product. It should only be obtained through licensed healthcare providers and pharmacies. Do not attempt to source through RUO or gray-market channels.
Evidence visual
PT-141 evidence and risk matrix
advanced researcher fit
Evidence
Tier A
Risk
low
Regulatory
rx approved
WADA
none
FDA
none
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
PT-141 (bremelanotide), sold as Vyleesi, is an FDA-approved nonselective melanocortin receptor agonist indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as 1.75 mg subcutaneous ~45 minutes before anticipated sexual activity. Contraindicated in uncontrolled hypertension or cardiovascular disease. Common AEs include nausea, flushing, injection site reactions, headache, and vomiting. Not indicated for men or postmenopausal women.
Decision path
Where PT-141 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether PT-141 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Nonselective melanocortin receptor agonist (MC1R, MC4R binding); exact mechanism for HSDD improvement unknown.
subcutaneous
Label: 1.75 mg subcutaneous as needed, ~45 min before anticipated activity. Max frequency limits apply.
Improved sexual desire in premenopausal women with acquired generalized HSDD.
Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose.
Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products.
Nausea, flushing, injection site reactions, headache, vomiting. BP elevation.
Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone.
Cost at a glance
Typical cycle cost
€27.29
Estimated monthly
€27.29
Protocol style
Intermittent / on-demand
Intermittent
Estimate confidence
High confidence
Assumes roughly 7 mg–14 mg per cycle, using 1 tracked affiliated listing.
Modeled as monthly on-demand use rather than daily administration.
Age, sex, and monitoring
Life-stage fit
Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern.
Best fit age ranges: 25-34, 35-44, 45-54
65+
Use becomes harder to justify when blood-pressure and cardiovascular tolerance are uncertain.
Sex-specific note
The clearest sex-specific peptide in the catalog: FDA-approved for premenopausal women with HSDD and not approved for men.
male
Not recommended in this planner because PT-141 has no approved male indication and the strongest evidence is female-specific.
other
Recommendation logic stays conservative because the strongest evidence and approval boundary are female-specific.
female
Avoid in pregnancy and use more caution with cardiovascular history because blood-pressure effects matter.
Monitoring burden
mediumThe main monitoring issue is cardiovascular tolerance and overall side-effect fit rather than broad lab surveillance.
Baseline labs and checks
blood pressure baseline, cardiovascular history review
Follow-up cadence
Review tolerance early and reassess if use becomes frequent.
Red flags
- marked blood-pressure rise
- severe nausea
- headaches with cardiovascular symptoms
Known Interactions
Two melanocortin agonists; FDA reports serious adverse events for melanotan II; Rx bremelanotide has cardiovascular contraindications/warnings.
Melanocortin agonist overlap; conservative caution.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for PT-141.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.